At 10 mg weekly, a 30 mg vial at 10 mg/mL provides three doses, covering three weeks
They could not determine whether obesity lowers B12 levels or if low B12 levels predispose someone to obesity
These observations indicate the criticalness of intrinsic axonal properties for successful CNS regeneration, independent of external inhibitory factors
Who should use BPC-157 and when
Weight loss peptides (GLP-1 agonists) Examples : Semaglutide, Tirzepatide, Liraglutide Common side effects (mostly GI-related): Nausea : Frequency: 40-50% of users initially Severity: Mild to moderate Duration: Usually 1-3 weeks (improves with continued use) Management: Start low dose, increase gradually, eat smaller meals Constipation : Frequency: 20-30% of users Severity: Mild to moderate Management: Increase fiber, water, consider stool softener Diarrhea : Frequency: 15-20% of users Severity: Mild Duration: Usually temporary Management: Probiotics, reduce fatty foods Fatigue : Frequency: 20-30% initially Severity: Mild to moderate Duration: 2-4 weeks (improves as caloric deficit stabilizes) Management: Adequate protein, electrolytes, patience Reduced appetite (intended effect): Not a side effect - this is the mechanism Goal: 15-20% reduction in caloric intake Result: Weight loss Read our semaglutide vs tirzepatide comparison
